Many of the therapeutic targets important in common adult cancers are also important for osteosarcoma and Ewing sarcoma. |
Preclinical and early clinical trial data are available to support the use of many of these agents in children. |
Combination therapy has generally been safe in children and should be evaluated further with more agents. |
1 Introduction
2 Surface Markers for Osteosarcoma (OS): Receptor Tyrosine Kinases
2.1 Insulin-Like Growth Factor Receptor Type I (IGF-1R)
Target | Class | Drug | Clinical trial | Age (y) |
---|---|---|---|---|
IGF-1R | Anti-IGF-1R antibodies | Cixutumumab with temsirolimus | Phase II: Recurrent or refractory solid tumors in pediatric patients (NCT01614795) | >1 to 30 |
VEGF/VEGFR | Anti-VEGF antibodies | Bevacizumab with chemotherapy | Phase II: OS (NCT00667342) [180] | Up to 30 |
Bevacizumab with chemotherapy | Phase II: ES family of tumor and desmoplastic small round cell tumors (NCT01610570) | >1 | ||
VEGF inhibitors | Endostar (recombinant human endostatin) with chemotherapy | Phase II: OS (NCT01002092) | 12–60 | |
Small-molecule TKIs | Pazopanib | Phase II: OS metastatic to the lung (NCT01759303) | >60 | |
Pazopanib | Phase II: Refractory solid tumors in children, adolescents, and young adults (NCT01956669) | >1 to 18 | ||
Regorafenib | Phase II: Refractory liposarcoma, OS, and ES (NCT02048371) | >18 | ||
Sorafenib with irinotecan | Phase I: Relapsed or refractory solid tumors in pediatric patients (NCT01518413) | 2–22 | ||
Sorafenib with everolimus | Phase II: Relapsed and non-resectable high-grade OS (NCT01804374) [181] | >18 | ||
PDGFR | Small-molecule TKIs | Imatinib mesylate | Phase II: Refractory or relapsed solid tumors in children (NCT00030667) | Up to 30 |
Dasatinib | Phase II: Advanced sarcomas including ES (NCT00464620) | >13 | ||
Dasatinib with ipilimumab | Phase I: Advanced sarcomas including OS and ES (NCT01643278) | >18 | ||
HDACi | Small-molecule inhibitors of histone deacetylase | Vorinostat, docetaxel, and gemcitabine | Phase Ib/II: Advanced sarcoma | >18 |
Vorinostat and etoposide | Phase I/II: Relapsed/refractory sarcomas | <4 to 21 | ||
Valproic acid and bevacizumab with gemcitabine and docetaxel | Phase I/II: Locally advanced, unresectable or metastatic sarcoma (NCT01106872) Note: this is a combination of HDACi with VEGF inhibition | >18 | ||
Bone metabolism | Bisphosphonates | Zoledronic acid/zoledronic acid with ‘standard chemotherapy’ | Phase II/III: High-grade OS (NCT00691236) | 18–65 |
Zoledronic acid with chemotherapy | Phase III: High-grade OS (NCT00470223) | 5–50 | ||
Zoledronic acid with busulfan | Phase III: Localized and disseminated ES (NCT00987636) | 4–50 | ||
Conjugated radioisotopes | 153SM-EDTMP with external beam radiotherapy | Phase II: High-risk OS (NCT01886105) | 13–65 | |
Radium-223 dichloride | Phase I/II: High-risk OS (NCT01833520) | >15 | ||
mTOR | Small-molecule inhibitors | Everolimus | Phase II: Refractory or relapsed OS (NCT01216826) | Up to 21 |
Sirolimus with chemotherapy | Phase I: Recurrent and refractory solid tumors in children (NCT01331135) | Up to 30 | ||
Sirolimus with cyclophosphamide | Phase II: Advanced sarcomas including OS and ES (NCT00743509) | >16 | ||
Notch | Gamma secretase inhibitors | RO4929097 with vismodegib | Phase I/II: Advanced or metastatic sarcoma including OS and ES (NCT01154452) | >18 |
Hedgehog | Hedgehog signaling antagonists | Vismodegib with RO4929097 | See above | >18 |
Src | Small-molecule inhibitors | Saracatinib | Phase II: Recurrent OS localized to the lung (NCT00752206) | 15–74 |
PARP | PARP inhibitors/alkylating agents | Olaparib with temozolomide | Phase I: Recurrent or metastatic ES following failure of prior chemotherapy (NCT01858168) | >18 |
Olaparib | Phase II: Recurrent of metastatic ES following failure of prior chemotherapy (NCT01583543) [182] | >18 | ||
Niraparib with temozolomide | Phase I: Previously treated, incurable ES (NCT02044120) | >13 | ||
BMN-673 with temozolomide | Phase I/II: Refractory or recurrent malignancies including ES in younger patients (NCT02116777) | 13–30 | ||
Immunotherapy | Interferons | Low-dose IFNα-2b with thalidomide | Phase II: Soft tissue sarcoma or bone sarcoma (NCT00026416) | >18 |
Immunostimulants | Aerosol IL-2 | Phase I/II: Pulmonary metastases of solid tumors including OS and ES (NCT01590069) | 12–50 | |
GD2-based therapies | Activated T cells armed with GD2-bispecific antibody | Phase I/II: OS and neuroblastoma in children and young adults (NCT02173093) | >1 to 29 | |
Humanized anti-GD2 antibody (HU14.18K233A) | Phase I: OS and ES in children and adolescents (NCT00743496) [183] | Up to 21 | ||
T cells expressing an anti-GD2 chimeric antigen receptor | Phase I: GD2+ solid tumors in children and young adults (NCT02107963) | 1–35 |